Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Net Cash Flow (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Net Cash Flow for 11 consecutive years, with -$39.8 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 157.91% to -$39.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$35.2 million through Dec 2025, up 6.25% year-over-year, with the annual reading at -$35.2 million for FY2025, 6.25% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$39.8 million at Intellia Therapeutics, down from $37.2 million in the prior quarter.
  • The five-year high for Net Cash Flow was $385.7 million in Q4 2022, with the low at -$229.4 million in Q1 2023.
  • Average Net Cash Flow over 5 years is $148100.0, with a median of -$8.6 million recorded in 2022.
  • The sharpest move saw Net Cash Flow crashed 1629.85% in 2023, then surged 459.45% in 2025.
  • Over 5 years, Net Cash Flow stood at -$211.5 million in 2021, then soared by 282.4% to $385.7 million in 2022, then plummeted by 84.61% to $59.4 million in 2023, then grew by 15.7% to $68.7 million in 2024, then tumbled by 157.91% to -$39.8 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$39.8 million, $37.2 million, and $21.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.